Timothy Ryan Barnes, PTA | |
8220 Matisse St Apt 1507, Champions Gate, FL 33896-8380 | |
(181) 348-2180 | |
Not Available |
Full Name | Timothy Ryan Barnes |
---|---|
Gender | Male |
Speciality | Physical Therapy Assistant |
Location | 8220 Matisse St Apt 1507, Champions Gate, Florida |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346984861 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2081H0002X | Physical Medicine & Rehabilitation - Hospice And Palliative Medicine | 27043 (Florida) | Secondary |
225200000X | Physical Therapy Assistant | 27043 (Florida) | Primary |
Mailing Address | Practice Location Address |
---|---|
Timothy Ryan Barnes, PTA 12170 Cortez Blvd, Brooksville, FL 34613-5578 Ph: (352) 279-4166 | Timothy Ryan Barnes, PTA 8220 Matisse St Apt 1507, Champions Gate, FL 33896-8380 Ph: (181) 348-2180 |
News Archive
Experts from across the world will meet to discuss the implementation of a pioneering non-invasive test to determine the blood type of unborn babies at an event hosted by the University of Warwick.
In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.
Researchers at Binghamton University, State University of New York have uncovered the unique way in which a type of Gram-negative bacterium delivers the toxins that make us sick. Understanding this mechanism may help design better ways to block and eventually control those toxins.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 55,223 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September 6, 2005.
› Verified 8 days ago